BioMendics

Mariposa Therapeutics

This biotechnology company develops a topical small-molecule therapy for patients with the rare genetic skin condition epidermolysis bullosa simplex.

Castle Creek Biosciences

This company develops cell and gene therapies for patients suffering from rare genetic skin and connective tissue diseases.

Xinnate

Xinnate develops peptide-based topical therapies for patients with inflammatory skin diseases and chronic wounds, primarily focusing on treating epidermolysis bullosa.

RougeTx

This biotechnology company develops small-molecule therapies that restore vascular stability to treat patients with hereditary haemorrhagic telangiectasia and other bleeding disorders.

GondolaBio

This biopharmaceutical company develops clinical-stage and preclinical medicinal therapeutics for patients living with rare genetic diseases.

Orvida Pharma (Formerly Kamari)

This biotechnology company develops oral and topical small-molecule treatments for patients with rare and severe genetic skin diseases and chronic itch conditions.

Scenic Biotech

This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.

Atavistik Bio

This biotechnology company develops oral allosteric small molecule therapeutics for patients with rare hematological diseases and cancers.